M-EDG's Florida-Israel Biomedical Initiative
U.S. Commercialization for Israel's Biomedical Products

The FL-IBI provides a very well-suited marketing and distribution vehicle for the U.S. commercialization of Israelࢩomedical devices and products.*  The main benefits to the Israeli biomedical companies seeking U.S. distribution relates to M-EDG༩>Equity-based Business Model
ﳰan>,  which provides significant equity/ownership rather than simply a royalty under a conventional licensing agreement.

The main benefits to the Israeli companies and their owners are:

  • Significantly greater participation in successful U.S. commercialization

  • From 20 to 30 times greater ROI for equity interests in Israeli biomedical companies

  • Post-commercialization Israeli majority-ownership potential

  • Increased U.S. recognition of Israelలeeminent biomedical product development expertise.


NOTE: In order to successfully commercialize medical products in the U.S. healthcare industry, it is vital to successfully manage over a dozen functional areas in addition to marketing and distribution and to have had significant experience and responsibility in managing each of these typically interrelated functional areas.payreplicawatch (For a listing of these dozen areas, note the "What We Do" page of this website.) The senior management of M-EDG, the parent of the Florida--Israel Biomedical Initiative, possesses well over 200 man-years of hands-on and senior management responsibility for these dozen-plus functional areas.

 

CLICK HERE to read a list of incredible scientific and technology breakthroughs
that were developed by and in the nation of Israel.

Israel 101 is produced by Stand With Us, and provides an excellent introduction and historical perspective to many of the issues facing Israel and the world.
NOTE:  Clicking the Israel 101 link will open a new window.  M-EDG is not responsible for the content of external websites.

<